Study population: clinical trials with tositumomab and iodine I131 tositumomab in patients with low-grade and transformed low-grade NHL and their respective follow-up times
Study . | No. patients . | No. prior therapies, median (range) . | Median follow-up from diagnosis, y (range) . | Median follow-up from RIT, y (range) . |
|---|---|---|---|---|
| Previously treated | ||||
| RIT-I-000 | 22 | 5 (1-13) | 10.1 (1.0-25.5) | 3.8 (0.2-9.8) |
| RIT-II-001 | 47 | 4 (1-13) | 7.5 (1.8-27.7) | 2.8 (<0.1-7.2) |
| RIT-II-002 | 61 | 2 (1-8) | 5.8 (1.1-23.3) | 3.2 (0.2-6.0) |
| RIT-II-004 | 60 | 4 (2-13) | 7.7 (2.4-29.0) | 2.5 (<0.1-5.9) |
| CP-97-012 | 40 | 4 (2-13) | 7.2 (1.8-17.7) | 3.2 (0.1-4.6) |
| CP-98-020 | 765 | 2 (1-12) | 5.8 (0.6-27.1) | 1.9 (<0.1-4.5) |
| Total | 995 | 3 (1-13) | 6.1 (0.6-29.0) | 2.0 (<0.1-9.8) |
| Previously untreated | ||||
| RIT-II-003 | 76 | 0 (0-0) | 5.6 (1.1-14.2) | 4.6 (0.6-6.7) |
Study . | No. patients . | No. prior therapies, median (range) . | Median follow-up from diagnosis, y (range) . | Median follow-up from RIT, y (range) . |
|---|---|---|---|---|
| Previously treated | ||||
| RIT-I-000 | 22 | 5 (1-13) | 10.1 (1.0-25.5) | 3.8 (0.2-9.8) |
| RIT-II-001 | 47 | 4 (1-13) | 7.5 (1.8-27.7) | 2.8 (<0.1-7.2) |
| RIT-II-002 | 61 | 2 (1-8) | 5.8 (1.1-23.3) | 3.2 (0.2-6.0) |
| RIT-II-004 | 60 | 4 (2-13) | 7.7 (2.4-29.0) | 2.5 (<0.1-5.9) |
| CP-97-012 | 40 | 4 (2-13) | 7.2 (1.8-17.7) | 3.2 (0.1-4.6) |
| CP-98-020 | 765 | 2 (1-12) | 5.8 (0.6-27.1) | 1.9 (<0.1-4.5) |
| Total | 995 | 3 (1-13) | 6.1 (0.6-29.0) | 2.0 (<0.1-9.8) |
| Previously untreated | ||||
| RIT-II-003 | 76 | 0 (0-0) | 5.6 (1.1-14.2) | 4.6 (0.6-6.7) |